Mutagenesis Advance Access published online on November 15, 2005
Mutagenesis, doi:10.1093/mutage/gei062
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Johnson&Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, Department of ADME/TOX, B-2340 Beerse, Belgium
* To whom correspondence should be addressed. In this paper we describe an initial reproducibility study of 12 proprietary compounds followed by the assessment of 51 marketed pharmaceuticals and, lastly, a summary of the data so far from 2698 proprietary compounds from the Johnson & Johnson (J&J) compound library, in the yeast GreenScreen® assay (GSA). In this assay, a reporter system in the yeast cells employs the DNA damage inducible promoter of the RAD54 gene, fused to the extremely stable green fluorescent protein (GFP). The assay proved to be very robust, the Excel templates provided by Gentronix with the assay interfaced well with in-house J&J systems with little adaptation, the assay was very rapid to perform and used very little compound. The results confirm previous work which suggests that the yeast GSA detects different classes of genotoxic compounds to the Ames assay and as a result can help screen out important genotoxic compounds at the pre-regulatory test phase that are missed by Ames-test-based screens alone. A combination of SAR evaluation of genotoxicity plus an Ames-test-based screen and the GSA provides a powerful pre-regulatory test battery to aid in the selection of successful drug candidates.
Received July 18, 2005
Revised October 10, 2005
Accepted October 13, 2005
Original article
An assessment of the utility of the yeast GreenScreen assay in pharmaceutical screening
J. Van Gompel 1,
F. Woestenborghs 1,
D. Beerens 1,
C. Mackie 1,
P. A. Cahill 2,
A. W. Knight 2,
N. Billinton 2,
D. J. Tweats 3,
and
R. M. Walmsley 2 *
2 Faculty of Life Sciences, University of Manchester, Jackson's Mill, Manchester M60 1QD, UK
3 Genetics Department, University of Wales Swansea, Singleton Park, Swansea SA2 8PP, UK
R. M. Walmsley, E-mail: richard.walmsley{at}manchester.ac.uk
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. W. Knight, L. Birrell, and R. M. Walmsley Development and Validation of a Higher Throughput Screening Approach to Genotoxicity Testing Using the GADD45a-GFP GreenScreen HC Assay J Biomol Screen, January 1, 2009; 14(1): 16 - 30. [Abstract] [PDF]
|
|
|
|
 |
|
 A. W. Knight, N. Billinton, P. A. Cahill, A. Scott, J. S. Harvey, K. J. Roberts, D. J. Tweats, P. O. Keenan, and R. M. Walmsley An analysis of results from 305 compounds tested with the yeast RAD54-GFP genotoxicity assay (GreenScreen GC) including relative predictivity of regulatory tests and rodent carcinogenesis and performance with autofluorescent and coloured compounds Mutagenesis, November 1, 2007; 22(6): 409 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Jacobson-Kram and J. F. Contrera Genetic Toxicity Assessment: Employing the Best Science for Human Safety Evaluation Part I: Early Screening for Potential Human Mutagens Toxicol. Sci., March 1, 2007; 96(1): 16 - 20. [Abstract] [Full Text] [PDF]
|
|